LoadingLoadingLoading26 funds hold it.Insiders net selling.
Net selling: insiders sold $28.8M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsLast report
Aug 4, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.83 expected
Revenue
Revenue data unavailable
Estimates as of Oct 30, 2026
EPS expected
-$0.85 to -$0.66
Revenue expected
16 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Jun 30, 2026Reported Aug 4, 2026 | -$0.73est. -$0.83 | +12.35%beat | Not on file | Not on file |
| Mar 31, 2026Reported May 5, 2026 | -$0.83est. -$0.86 | +3.61%beat | $60.1MYahoo Finance | No year-ago quarter |
| Dec 31, 2025Reported Feb 26, 2026 | -$0.73est. -$0.78 | +6.38%beat | $57.3MYahoo Finance | No year-ago quarter |
| Sep 30, 2025Reported Nov 4, 2025 | -$0.82est. -$0.73 | -11.72%miss | $51.3MYahoo Finance | No year-ago quarter |
| Jun 30, 2025Reported Aug 5, 2025 | -$0.75est. -$0.67 | -11.94%miss | Not on file | Not on file |
| Mar 31, 2025Reported May 7, 2025 | -$0.81est. -$0.68 | -19.12%miss | Not on file | Not on file |
| Dec 31, 2024Reported Feb 26, 2025 | -$0.72est. -$0.73 | +1.37%beat | Not on file | Not on file |
| Sep 30, 2024Reported Nov 5, 2024 | -$0.73est. -$0.87 | +16.09%beat | Not on file | Not on file |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $51.3M | $57.3M | $60.1M | $71.3M |
| Cost of what it sold | $5.5M | $4.8M | $7.2M | $8.9M |
| Gross profit | $45.8M | $52.5M | $53.0M | $62.3M |
| What it spent | ||||
| Research and development | $46.0M | $42.0M | $41.7M | $43.4M |
| Sales and admin | $52.4M | $57.5M | $63.6M | $67.4M |
| Total operating expenses | $98.5M | $99.5M | $105.3M | $110.9M |
| What was left | ||||
| Operating profit | -$52.7M | -$47.1M | -$52.4M | -$48.6M |
| Interest on debt | $4.7M | $4.6M | $4.6M | $4.5M |
| Profit before tax | -$52.8M | -$47.5M | -$55.1M | -$48.9M |
| Tax | $111.0K | -$31.0K | $545.0K | $444.0K |
| Net profit | -$52.9M | -$47.5M | -$55.6M | -$49.3M |
| EBITDA | -$47.7M | -$42.6M | -$50.3M | -$44.1M |
This stock is under pressure.
Trend
Under pressure
35 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
BullishOct 27How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Japan Drug Launch
Leans bullishOct 27Rhythm Pharmaceuticals (RYTM) Launched IMCIVREE In Japan, Is It Still A Bargain?
BullishOct 25Rhythm Pharmaceuticals, Inc. Estimates – NASDAQ:RYTM
NeutralOct 24Rhythm Pharmaceuticals, Inc. Estimates – FWB:1RV
NeutralOct 23Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
NeutralOct 22Two healthcare conferences will feature Rhythm’s CEO and CFO after its Nov. 3 results call.
NeutralOct 22Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
NeutralOct 22
